基于氨酸的小分子作为激酶抑制剂的最新进展 (2020-2024)
Sara Sultan1, Ruba A Zenati1, Hanan S Anbar2
1University of Sharjah, Medicinal Chemistry, UNITED ARAB EMIRATES.
ChemMedChem
|May 13, 2025
概括
昆化合物是癌症治疗的有效激酶抑制剂. 最近的研究 (2020-2024) 强调了它们的设计,合成和优化,以准癌症信号通路.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 奎诺林支架在药物化学中至关重要,特别是用于开发激酶抑制剂.
- 激酶抑制剂通过向异常信号通路,对治疗各种癌症至关重要.
- 最近的进展集中在oline衍生物,因为它们的宽谱激酶抑制活性.
研究的目的:
- 审查近期 (2020-2024) 基于林的激酶抑制剂对癌症的进展.
- 突出这些化合物的设计,合成和优化策略.
- 讨论它们在向关键激酶中的作用及其临床相关性.
主要方法:
- 从2020年到2024年的研究文献综述.
- 对林衍生物的抑制活性和选择性概况的分析.
- 对关键化合物的药理数据的汇编.
主要成果:
- 昆衍生物对广泛的激酶具有显著的抑制活性.
- 在临床瘤学中使用了几种FDA批准的含金林的激酶抑制剂.
- 关键化合物表现出强大的活性,选择性和有希望的临床前/临床结果.
结论:
- 基于昆的激酶抑制剂代表了下一代抗癌疗法的一个有希望的领域.
- 通过先进的药物设计和组合疗法进行进一步优化是有必要的.
- 这些抑制剂具有破坏癌症生长和进展的巨大潜力.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Drug Discovery: Overview
7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K


